Ekso Bionics (NYSE: EKSO) — Perfil da empresa, notícias e dados financeiros
Ekso Bionics develops exoskeleton solutions for enhanced mobility in medical and industrial applications.
Ekso Bionics
Ekso Bionics (NASDAQ:EKSO) specializes in the development and production of exoskeleton solutions aimed at enhancing human mobility and strength for industrial, medical, and military applications. The company is primarily known for its cutting-edge robotic suits that assist individuals with spinal injuries and stroke survivors in walking again, along with devices that improve productivity and reduce injury risk for workers performing physically demanding tasks. Ekso Bionics is committed to pioneering innovations that can transform lives by boosting mobility, strength, and endurance, thereby pushing the boundaries of what is possible in human-machine collaboration.
Resumo
Operações
Produtos e/ou serviços de Ekso Bionics
- EksoNR, a wearable exoskeleton designed for rehabilitation in individuals with neurological conditions.
- EksoVest, an upper body exoskeleton aimed at reducing workplace strain and injuries.
- EksoUE, an upper extremity exoskeleton for stroke and spinal cord injury rehabilitation.
- EksoZeroG, a support arm for heavy tools, enhancing worker safety and productivity.
- EksoPulse, a cloud-based data analytics platform for monitoring and improving the use of their exoskeletons.
equipe executiva do Ekso Bionics
- Mr. Scott G. DavisCEO & Director
- Mr. Jerome WongCFO & Corporate Secretary
- Mr. Jason C. JonesChief Operating Officer
- Ms. Lisa BentleyHead of Marketing
- Ms. Ann CooksonHuman Resources Director
- Mr. Stephan AderholdSenior VP & GM of EMEA
- Ms. Katherine StrausserPrincipal Controls Engineer
Principais indicadores financeiros
Resultados divulgados pela Ekso Bionics, em USD.
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 12,8 mi | -13,3 mi | -11,7 mi | |
| 17,9 mi | -10,5 mi | -11,3 mi | |
| 18,3 mi | -15,1 mi | -15,2 mi | |
| 12,9 mi | -15,6 mi | -15,1 mi |